Albireo Pharma IncのRPE
Albireo Pharma IncのRPEは何ですか。
Albireo Pharma IncのRPEは441.469k$です。
RPEの定義は何ですか。
従業員1人当たりの収益（RPE）は、収益を組織の従業員の数で割ったものです。
NASDAQのセクタHealth CareにおけるRPEの企業と比べるAlbireo Pharma Inc
Albireo Pharma Incは何をしますか。
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Incと類似のrpe
- SanofiのRPEは440.466k€です。
- SanofiのRPEは440.466k€です。
- Ashtead PlcのRPEは440.641k$です。
- Baofeng Modern InternationalのRPEは440.836k¥です。
- GreenSky IncのRPEは441.290k$です。
- The Heavitree Brewery PLCのRPEは441.375k£です。
- Albireo Pharma IncのRPEは441.469k$です。
- SB IncのRPEは441.496k$です。
- LendingTreeのRPEは441.727k$です。
- Yu Tak InternationalのRPEは441.739kHKD$です。
- Jiumaojiu InternationalのRPEは441.807k¥です。
- Anaergia IncのRPEは441.932kCAD$です。
- AMG Advanced Metallurgical NVのRPEは441.948k$です。